Healthcare provider profile · identity verified

Harpreet K Johl, MD

Family Practice · OLIVEHURST, CA · NPI 1053423202

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	595	122
Eliquis	Apixaban	381	39
Amlodipine Besylate	Amlodipine Besylate	319	76
Furosemide	Furosemide	319	59
Levothyroxine Sodium	Levothyroxine Sodium	314	68
Potassium Chloride	Potassium Chloride	302	52
Losartan Potassium	Losartan Potassium	249	66
Gabapentin	Gabapentin	244	54
Lisinopril	Lisinopril	206	52
Metformin Hcl	Metformin Hcl	206	60
Omeprazole	Omeprazole	191	55
Pantoprazole Sodium	Pantoprazole Sodium	190	45
Metoprolol Tartrate	Metoprolol Tartrate	166	47
Metoprolol Succinate	Metoprolol Succinate	147	34
Escitalopram Oxalate	Escitalopram Oxalate	112	21
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	112	31
Januvia	Sitagliptin Phosphate	110	18
Clopidogrel	Clopidogrel Bisulfate	109	22
Quetiapine Fumarate	Quetiapine Fumarate	92	15
Donepezil Hcl	Donepezil Hcl	89	14
Hydralazine Hcl	Hydralazine Hcl	87	22
Simvastatin	Simvastatin	85	17
Finasteride	Finasteride	78	16
Rosuvastatin Calcium	Rosuvastatin Calcium	72	16
Xarelto	Rivaroxaban	71	suppressed
Duloxetine Hcl	Duloxetine Hcl	68	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	66	20
Mirtazapine	Mirtazapine	65	16
Albuterol Sulfate Hfa	Albuterol Sulfate	56	24
Allopurinol	Allopurinol	55	13
Alendronate Sodium	Alendronate Sodium	53	suppressed
Azithromycin	Azithromycin	53	43
Digoxin	Digoxin	51	suppressed
Glimepiride	Glimepiride	50	12
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	50	20
Isosorbide Mononitrate Er	Isosorbide Mononitrate	49	suppressed
Trazodone Hcl	Trazodone Hcl	49	17
Sertraline Hcl	Sertraline Hcl	48	13
Fluticasone Propionate	Fluticasone Propionate	46	19
Lantus	Insulin Glargine,hum.Rec.Anlog	46	suppressed
Lorazepam	Lorazepam	46	17
Alprazolam	Alprazolam	45	suppressed
Tradjenta	Linagliptin	44	suppressed
Memantine Hcl	Memantine Hcl	42	suppressed
Pregabalin	Pregabalin	41	12
Latanoprost	Latanoprost	40	suppressed
Montelukast Sodium	Montelukast Sodium	39	12
Amiodarone Hcl	Amiodarone Hcl	38	11
Fluoxetine Hcl	Fluoxetine Hcl	38	suppressed
Risperidone	Risperidone	38	suppressed
Bumetanide	Bumetanide	37	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	34	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	34	13
Jardiance	Empagliflozin	34	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	34	suppressed
Carvedilol	Carvedilol	33	11
Fenofibrate	Fenofibrate	32	suppressed
Linzess	Linaclotide	32	suppressed
Aripiprazole	Aripiprazole	31	suppressed
Tramadol Hcl	Tramadol Hcl	31	suppressed
Levetiracetam	Levetiracetam	30	suppressed
Buspirone Hcl	Buspirone Hcl	29	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	28	suppressed
Spironolactone	Spironolactone	28	suppressed
Ezetimibe	Ezetimibe	27	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	27	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	27	suppressed
Clonazepam	Clonazepam	25	suppressed
Sucralfate	Sucralfate	24	suppressed
Baclofen	Baclofen	22	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	22	suppressed
Fenofibrate	Fenofibrate,micronized	21	suppressed
Ropinirole Hcl	Ropinirole Hcl	21	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	21	15
Valsartan	Valsartan	21	suppressed
Cephalexin	Cephalexin	20	13
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	20	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	19	suppressed
Ondansetron Odt	Ondansetron	19	13
Breo Ellipta	Fluticasone/Vilanterol	18	suppressed
Ibandronate Sodium	Ibandronate Sodium	18	suppressed
Albuterol Sulfate	Albuterol Sulfate	17	12
Famotidine	Famotidine	17	suppressed
Warfarin Sodium	Warfarin Sodium	17	suppressed
Folic Acid	Folic Acid	16	suppressed
Glipizide	Glipizide	16	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	16	13
Hydrocortisone	Hydrocortisone	15	suppressed
Nifedipine Er	Nifedipine	15	suppressed
Bupropion Xl	Bupropion Hcl	14	suppressed
Citalopram Hbr	Citalopram Hydrobromide	14	suppressed
Clonidine Hcl	Clonidine Hcl	14	suppressed
Droplet Pen Needle	Pen Needle, Diabetic	14	suppressed
Insulin Lispro	Insulin Lispro	14	suppressed
Labetalol Hcl	Labetalol Hcl	14	suppressed
Lamotrigine	Lamotrigine	14	suppressed
Memantine Hcl Er	Memantine Hcl	14	suppressed
Timolol Maleate	Timolol Maleate	14	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	13	11
Budesonide	Budesonide	13	suppressed
Cinacalcet Hcl	Cinacalcet Hcl	13	suppressed
Cyclosporine	Cyclosporine	13	suppressed
Febuxostat	Febuxostat	13	suppressed
Meloxicam	Meloxicam	13	suppressed
Metformin Hcl Er	Metformin Hcl	13	suppressed
Multaq	Dronedarone Hcl	13	suppressed
Mupirocin	Mupirocin	13	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	13	suppressed
Ozempic	Semaglutide	13	suppressed
Terazosin Hcl	Terazosin Hcl	13	suppressed
Tresiba Flextouch U-200	Insulin Degludec	13	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	12	11
Doxycycline Hyclate	Doxycycline Hyclate	12	11
Ibuprofen	Ibuprofen	12	suppressed
Trulicity	Dulaglutide	12	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	11	suppressed
Autoshield Duo Pen Needle	Pen Needle,dual Safety,diabetc	11	suppressed
Dabigatran Etexilate	Dabigatran Etexilate Mesylate	11	suppressed
Diclofenac Sodium	Diclofenac Sodium	11	suppressed
Dilt-Xr	Diltiazem Hcl	11	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	11	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	11	suppressed
Lumigan	Bimatoprost	11	suppressed
Telmisartan	Telmisartan	11	suppressed
Vascepa	Icosapent Ethyl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error